Pharminent

Lilly offers up drug pricing details amid ongoing scrutiny of industry

Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report. http://www.biopharmadive.com/news/Eli-lilly-pricing-report/438474/

Filed under: Pricing